Pfizer Clinical Research Unit
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The site is advancing research in heart failure with preserved ejection fraction, aiming to evaluate innovative therapies that could improve cardiac function and patient quality of life.
- Cardiac hemodynamics and biomarkers
- Patient‑reported outcome measures
- Novel drug delivery strategies
- Safety profiling in diverse populations
Pfizer Clinical Research Unit in Brussels supports these studies with state‑of‑the‑art facilities and expert investigators.
Digestive System Diseases
Investigators focus on ulcerative colitis and related inflammatory bowel conditions, seeking to test new oral agents that promote mucosal healing and reduce disease activity.
- Endoscopic assessment of inflammation
- Biomarkers of intestinal permeability
- Quality‑of‑life questionnaires
- Comparative efficacy of emerging therapies
The research team leverages a hybrid decentralized trial model to enhance patient participation.
Immune System Diseases
Studies address immune‑mediated inflammatory disorders such as rheumatoid arthritis and alopecia areata, aiming to expand treatment options that modulate immune pathways.
- Cytokine signaling inhibition
- Joint imaging and structural outcomes
- Skin autoimmunity assessments
- Long‑term safety monitoring
Pfizer’s Brussels unit collaborates with leading rheumatology and dermatology centers to accelerate these efforts.
Skin and Connective Tissue Diseases
The program explores therapies for atopic dermatitis, vitiligo, and related skin disorders, with the goal of restoring barrier function and pigmentation.
- Dermatologic scoring systems
- Pigment restoration metrics
- Immune cell profiling in skin tissue
- Patient‑centered outcome measures
Research at the Pfizer Clinical Research Unit combines clinical expertise with innovative trial designs to improve patient outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Pfizer Inc.14trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Pfizer Clinical Research Unit
lock Showing 1 of 14 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Evaluation of Carbamazepine's Impact on the Pharmacokinetics of Vepdegestrant in Healthy Adults with ER+/HER2+ Breast Cancer | Pfizer Inc. | Phase I | Not Recruiting | Aug 2023 | Nov 2023 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Etrasimod Arginine | 1 | Unknown | 2023-08-23 | 2023-08-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.